Skip to main content
. 2017 Apr 20;66(7):1999–2006. doi: 10.2337/db17-0100

Figure 1.

Figure 1

GFR (creatinine clearance) and urinary excretion of sodium and chloride in subjects without diabetes and with T2DM at baseline, on the day that empagliflozin (EMPA) was started (day 0), and during the 24–48-h period (day 1) after the start of empagliflozin. *P < 0.01 vs. baseline; †P < 0.05 vs. baseline.